Genetic Engineering & Biotechnology News (GEN), the only high-frequency publication dedicated to biotech news, from bench to business, was introduced in 1981 as the first biotechnology trade publication. Now in its 28th year, GEN retains its position as the most widely read biotechnology publication around the globe.
Published 21 times a year, GEN's unique news and technology content focus includes the entire bioproduct life cycle from early-stage R&D to applied research and bioprocess through to commercialization. GEN is the only publication that provides the full range of the biotechnology market coverage in areas such as omics, drug and biomarker discovery, bioprocessing, clinical research, molecular diagnostics, and biobusiness.
Genetic Engineering & Biotechnology News is an integrated media publication, available in both print and online. GEN's comprehensive coverage includes industry-standard tutorials and technical articles in bioprocessing, assays, and drug discovery; feature articles on emerging technologies; product roundups and regional biofocus articles on biotech hotbeds; and reports from key scientific and industry meetings.
Our acclaimed columns, available both in print and online, include Wall Street BioBeat, Financial Focus, Point of View, Corporate Profile, Biomarket Trends, Legal Affairs, and Best of the Web. Other regular, informative features in our pages and online include New Product listings, Classifieds, and a comprehensive and up-to-date notice of bioscience and bioindustry meetings in the Calendar of Events column.
In addition to the outstanding online coverage, GEN's print edition also features the following: Clinical Trials Update, Genomics & Proteomics news, Discovery and Development Briefs, Bioprocessing Highlights, Spotlight on Molecular Diagnostics, Inside Industry, Product and Service Deals, and People. These columns keep readers up-to-date on international industry announcements and events.
Genetic Engineering & Biotechnology News is published by Mary Ann Liebert, Inc., the leading publisher of authoritative peer-reviewed journals as well as books and directories in biotechnology, biomedical research, clinical medicine, surgery, and healthcare.
GEN print issues are published 21 times a year—twice monthly, and one issue each in July, August, and December.
"I have been a reader of GEN for many years and I regard it as an essential source of up-to-date information. There is nothing else like it! It keeps us in touch with new opportunities and is invaluable."
—Professor Sir Ian Wilmut University of Edinburgh
“Genetic Engineering News and Biotechnology News (GEN) is one of the most important media for keeping abreast of the cutting-edge developments in the field of biotechnology. I read it religiously and look forward to each issue with enthusiasm. The graphics are quite enjoyable and informative--if you are in biotechnology you need to read GEN.”
—David B. Weiner, Ph.D. University of Pennsylvania
GEN's comprehensive overviews of hot areas in biotech make it a “must read” for me and my colleagues.
—Arthur M. Krieg, Ph.D. Coley Pharmaceutical Group
Thank you for continuing to produce a premier information source for our growing industry. GEN has the unique capability to integrate innovative technology with recent results and business trends. I look forward to my next issue.
—Alan J. Russell, Ph.D. McGowan Institute for Regenerative Medicine
Subscribe to RSS